Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12967118 | 0.80 | USP2 (0.40) | TSHRADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL4077931 | 0.78 | MAPT (0.35) | TSHRADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL21101250 | 0.76 | CHRM2 (0.38) | — | |
| SCHEMBL1106473 | 0.76 | ADORA2A (0.35) | ADORA3ADORA2AADORA2BADORA1FPR2 | |
| SCHEMBL13439283 | 0.76 | ADORA3 (0.33) | ADORA3ADORA2AADORA2BADORA1FPR2 | |
| SCHEMBL5654711 | 0.76 | ADORA3 (0.35) | ADORA3ADORA2AADORA2BADORA1OPRK1 | |
| SCHEMBL859290 | 0.76 | NR3C1 (0.33) | ADORA3ADORA2AADORA2BADORA1FPR2 | |
| SCHEMBL14254645 | 0.74 | KCNH2 (0.35) | TSHRADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL17676554 | 0.74 | TSHR (0.35) | TSHR | |
| SCHEMBL8264017 | 0.74 | TSHR (0.44) | TSHRCHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377974-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120178733-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-07-12 | — | — | US | disclosed |
| US-8153670-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153670-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8119654-B2 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119654-B2 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100179140-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100121049-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100121049-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-7696352-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7652028-B2 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| US-20100004220-A1 | Indenoisoquinolinone Analogs and Methods of Use Thereof | INOTEK PHARMACEUTICALS CORPORATION | 2010-01-07 | — | — | US | disclosed |
| US-20090298806-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-20090298806-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-7521470-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20080214593-A1 | TETRACYCLIC AMINO AND CARBOXAMIDO COMPOUNDS AND METHODS OF USE THEREOF | JAGTAP PRAKASH | 2008-09-04 | — | — | US | disclosed |
| WO-2008106619-A2 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2008-09-04 | — | — | WO | disclosed |
| US-7381722-B2 | Tetracyclic amino and carboxamido compounds and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2008-06-03 | — | — | US | disclosed |
| US-20070185092-A1 | FACTOR Xa INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185092-A1 | FACTOR Xa INHIBITORS | TFPI, F12, F11 | TSHR 2650/4885CHRNB2 4500/4885CHRNA4 4332/4885 |
| US-20080214593-A1 | TETRACYCLIC AMINO AND CARBOXAMIDO COMPOUNDS AND METHODS OF USE THEREOF | GLS, AADAT, IAPP | TSHR 2185/4885CHRNB2 4149/4885CHRNA4 3691/4885 |
| US-20090298806-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | TSHR 2852/4885CHRNB2 4779/4885CHRNA4 4482/4885 |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | TNNI3, IDH2, GLS | TSHR 4803/4885CHRNB2 617/4885CHRNA4 1346/4885 |
| US-20100121049-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | TNNI3, IDH2, GLS | TSHR 4803/4885CHRNB2 617/4885CHRNA4 1346/4885 |
| US-20120178733-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | TSHR 2852/4885CHRNB2 4779/4885CHRNA4 4482/4885 |
| US-20100004220-A1 | Indenoisoquinolinone Analogs and Methods of Use Thereof | TNNI3, IDH2, GLS | TSHR 4803/4885CHRNB2 617/4885CHRNA4 1346/4885 |
| US-20100179140-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | TNNI3, IDH2, GLS | TSHR 4803/4885CHRNB2 617/4885CHRNA4 1346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.